Greg Cosma, PhD
Scientific Advisory Board Member
Following a 20+ year career as a trusted senior leader in the pharmaceutical industry, most recently as Vice President of Genentech Research and Early Development, where he led the Safety Assessment organization and chaired their Development Review Committee, Greg is currently Owner and Principal of Cosma Biopharma Consulting, LLC. During his career in biopharma, spanning companies including Pfizer, BMS and Genentech, Greg has successfully managed and overseen the submission of > 100 INDs, and the approval of multiple drugs. Currently, Greg serves on Scientific Advisory Boards of biopharma companies, providing strategic and technical guidance for portfolio and drug development decision making.
Statement: “I am thrilled to participate in the Aarvik SAB, a company whose vision, passion and novel technology platforms I believe will catalyze transformational benefit to cancer patients”.